Developability, stability and formulation at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

49 organizations at PEGS Europe 2026 present work in developability, stability and formulation: 29 suppliers and service providers, 14 drug developers and 6 academic, government and non-profit bodies. Between them they bring 92 presentations to the program. Most represented: AstraZeneca (12 on the program), Roche (8 on the program), Novartis (6 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–6 of 49 organizations

Organization	PEGS Europe 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company with oncology, immunology, respiratory and rare disease medicines, including antibodies and ADCs.	Talk Tue Nov 17 9:30am–10:00am Building the Protein Lab of the Future at AstraZeneca: Automation First Science and AI Ready Data at Scale Leveraging Data Science for Enhanced Protein Expression Chair Tue Nov 17 11:44am–11:45am Chairperson's Remarks Display of Biologics Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks Display of Biologics Talk Tue Nov 17 5:20pm–5:50pm Machine Learning for Lead Optimisation Workflow (MeLLOw): Integrating in silico and Wet Lab Data for Biologics Engineering Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with Specifica, Merck KGaA, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Talk Tue Nov 17 5:50pm–6:20pm Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers T Cell Engagers Chair Wed Nov 18 8:25am–8:30am Chairperson’s Remarks Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:15am–11:45am Stability Prediction for Multispecific Antibodies Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:45am–12:15pm Application of Expression Strategies for Integral Membrane Protein Production Designing High-Performance Expression Platforms Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 8:30am–8:50am Evolutionary Algorithms for Peptide Design and Optimisation Novel Peptide Drug Discovery Talk Thu Nov 19 9:00am–9:30am Next-Generation Protein Characterisation: An Integrated Mass Spectrometry Strategy from Structured Proteins to Intrinsically Disordered Proteins Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 11:15am–11:45am Targeting Peptides for Enhanced Tissue Delivery Novel Peptide Drug Discovery Talk Thu Nov 19 11:45am–12:05pm AI for Biologics: Transition from Discovery to Design Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 5:15pm–5:45pm Optimal Design of Masks for Protease-Activated Biologics: What Works, What Doesn’t, and Why Next-Generation Immunotherapies
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company whose research units discover and develop antibodies, bispecifics and other biologic medicines.	Chair Tue Nov 17 8:25am–8:30am Chairperson's Remarks Optimisation & Developability Talk Tue Nov 17 11:45am–12:15pm Elucidating the Structure-PK Relationship of Complex Antibody Formats and Understanding the Underlying Mechanisms for Improved Drug Design Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Tue Nov 17 2:05pm–2:35pm From Molecules to Drug Readiness Optimisation & Developability Talk Wed Nov 18 9:30am–10:00am Characterisation of a Biparatopic Sweeping Antibody Biologics for Autoimmune Diseases Talk Wed Nov 18 2:35pm–3:05pm Next-Generation T Cell Engagers: Leveraging Protease Activation to Overcome Toxicity and Expand the Therapeutic Window Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand Advances in Immunoengineering Talk Wed Nov 18 6:25pm–6:50pm Robust Production of Virus-Like Particles in HEK293 Cell Lines Designing High-Performance Expression Platforms Talk Thu Nov 19 11:15am–11:45am Next-Generation FVIIIa-Mimetic Bispecific Antibody NXT007 for Hemophilia A: Evaluation in Preclinical Models Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 11:45am–12:15pm Insights into Fab Nebulisation: How to Minimise Aggregates for Inhaled Biologics Protein Stability & Formulation
Novartis Basel, Switzerland
novartis.com Large pharma Swiss pharmaceutical company with a large biologics pipeline across oncology, immunology, cardiovascular and neuroscience.	Talk Tue Nov 17 9:30am–10:00am In silico Approaches for siRNA AOC Optimisation Optimisation & Developability Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks Optimisation & Developability Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 9:00am–9:30am From Suspension to Signal: Enabling Analytical Characterisation of Therapeutic Proteins in High-Dose Non-Aqueous Suspension Formulations Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 6:00pm–6:30pm Design of Potency Assays in Development of Standard and Complex Biologics Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:30am–9:00am Mechanistic Understanding of an Unusually Stable Succinimide Intermediate in an Antibody Therapeutic Protein Stability & Formulation Chair Thu Nov 19 2:00pm–2:05pm Chairperson's Remarks Protein Stability & Formulation Panel Thu Nov 19 3:35pm–4:15pm High-Dose Options for the Diverse Biologics Modalities and the Unknowns Protein Stability & Formulation
Merck KGaA Darmstadt, Germany
merckgroup.com Large pharma German science and technology group whose healthcare business develops antibodies, ADCs and other biologics; it also runs a life science tools business.	Talk Tue Nov 17 3:05pm–3:35pm Integrating AI/ML and Next-Generation Sequencing for Accelerated Discovery of Single Domain Antibodies Display of Biologics Talk Tue Nov 17 4:50pm–5:20pm Digitalizing ADC Discovery: Building an Integrated Data and Workflow Platform Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with AstraZeneca, Specifica, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Chair Thu Nov 19 10:44am–10:45am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 10:45am–11:15am Decoding Photodegradation of ADC Payloads: Integrating in silico Modelling with Experimental Evidence to Understand and Predict Stability Protein Stability & Formulation Talk Thu Nov 19 4:45pm–5:15pm Multifunctional Antibody-Derived Receptor Agonists for Targeted Immunomodulation Next-Generation Immunotherapies
Sanofi Paris, France
sanofi.com Large pharma French pharmaceutical company developing antibodies, Nanobody molecules, multispecifics and other biologics across immunology, oncology and rare diseases.	Talk Wed Nov 18 9:30am–10:00am Structural Biology at the Forefront of Biotherapeutics: Cryo-EM, AI, and Complex Modalities Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 9:00am–9:30am Colloidal Stability Prediction of Multivalent NANOBODY Molecules Using Machine Learning Protein Stability & Formulation Chair Thu Nov 19 10:44am–10:45am Chairperson's Remarks Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 11:05am–11:25am De novo VHH Design in Practice: Bridging AI Innovation with Real-World Biologics Design Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 5:15pm–5:45pm Precision-Activated T Cell Engagers in Immuno-Oncology: Pharmacological Characterisation of Albumin-Masked TCR Multispecific VHHs Engineering the Next Generation of Bispecific Antibodies
Genentech South San Francisco, CA
gene.com Large pharma Roche group biotechnology company discovering and developing antibody and protein medicines in oncology, immunology and other areas.	Talk Tue Nov 17 11:45am–12:15pm Multi-Objective Antibody Optimisation with Property Enhancer (PropEn) Optimisation & Developability Talk Wed Nov 18 2:05pm–2:35pm AI-Based Analysis of Label-Free Live Cell Imaging of T Cell Mediated Tumour Killing Assay Enables Competitive and Robust Hit Calling Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 6:30pm–7:00pm SMACk: A Modular Platform for Sterically Masked Activated Cytokines Biologics for Autoimmune Diseases Talk Thu Nov 19 2:35pm–3:05pm Comparative Analysis of 4-1BB and CD28 Tumour-Targeted Co-Stimulation to Support T Cell Bispecific Antibody Therapy in Solid Tumours Engineering the Next Generation of Bispecific Antibodies